The Medical Advisor

Medically Reviewed by: OneDayMD Editorial Team | Last Updated: April 2026 In September 2024, a first-of-its-kind protocol utilizing ivermectin, fenbendazole, and mebendazole for cancer treatment was peer-reviewed and officially published in the Journal of Orthomolecular Medicine . Led by researchers Dr. Ilyes Baghli, Dr. Pierrick Martinez, and FLCCC's Dr. Paul Marik, the protocol applies antiparasitic drugs — originally developed to combat parasites — to cancer treatment, building on emerging preclinical and clinical evidence of their anticancer properties. This trio of repurposed drugs has been shown to disrupt the growth of cancer cells, particularly by targeting microtubules, the essential structures that allow cancer to multiply uncontrollably. What makes this protocol even more potent is the synergistic effect when these drugs are used together, creating a powerful new affordable weapon against cancer. Journal of Orthomolecular Medicine 2024 Targeting the Mitochondrial-Stem C...

OneDayMD Evidence Review Updated: August 2026 Article type: Narrative evidence review / systems-oncology framework Evidence status: Research framework; not a validated cancer treatment protocol Abstract Background: Cancer is not solely a genetic disease. Malignant cells can undergo profound changes in glucose metabolism, mitochondrial function, amino-acid utilization, lipid metabolism, redox biology and interactions with the immune microenvironment. These changes can influence tumor growth, treatment response and resistance. This has generated increasing interest in metabolic oncology. Objective: This review updates the OneDayMD seven-layer metabolic cancer framework and evaluates its major components according to the strength of available evidence. The framework integrates metabolic health, nutrition, standard tumor-directed therapy, investigational repurposed drugs, mitochondrial biology, cancer stem-cell biology, immune metabolism and lifestyle medicine. Methods: Evi...

AI recently announced to the world that Ivermectin is Ranked #1 in Metastatic Cancer Pathway blocking activity. Since then, AI has corroborated this as Ivermectin is also #1 in CSC Pathway blocking . Ivermectin is also the #1 repurposed drug in the Marik-Hope CSC Protocol s as it blocks or suppresses at least seven Key CSC (cancer stem cell) Signaling Pathways. Today, we share powerful evidence - helped by AI - in finding the precise Repurposed Drug Combinations that can prevent Stage 1 or Stage 2 cancers from progressing to deadly Stage 4 disease. And now, allow me to share AI’s astonishing confirmation of the protocols which Dr. Paul E. Marik and I developed following our last few years of research. I. Prostate Cancer This is the most common cancer in men. Slide Courtesy of Dr. Paul Marik While accounting for 27.3% of new cancer cases in men, Prostate Cancer has a nasty habit of metastasizing. Following early treatment with radical prostatectomy, most patients do well for a few yea...